447 related articles for article (PubMed ID: 22155184)
1. β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.
Satow R; Shitashige M; Jigami T; Fukami K; Honda K; Kitabayashi I; Yamada T
Gastroenterology; 2012 Mar; 142(3):572-81. PubMed ID: 22155184
[TBL] [Abstract][Full Text] [Related]
2. In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies.
Saitoh N; Uchimura Y; Tachibana T; Sugahara S; Saitoh H; Nakao M
Exp Cell Res; 2006 May; 312(8):1418-30. PubMed ID: 16688858
[TBL] [Abstract][Full Text] [Related]
3. ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.
Shin HW; Choi H; So D; Kim YI; Cho K; Chung HJ; Lee KH; Chun YS; Cho CH; Kang GH; Kim WH; Park JW
Gastroenterology; 2014 Aug; 147(2):430-442.e8. PubMed ID: 24846398
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Wnt signaling by the nuclear pore complex.
Shitashige M; Satow R; Honda K; Ono M; Hirohashi S; Yamada T
Gastroenterology; 2008 Jun; 134(7):1961-71, 1971.e1-4. PubMed ID: 18439914
[TBL] [Abstract][Full Text] [Related]
5. PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.
Ivanschitz L; Takahashi Y; Jollivet F; Ayrault O; Le Bras M; de Thé H
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):14278-83. PubMed ID: 26578773
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.
Herzer K; Weyer S; Krammer PH; Galle PR; Hofmann TG
Cancer Res; 2005 Dec; 65(23):10830-7. PubMed ID: 16322229
[TBL] [Abstract][Full Text] [Related]
7. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
[TBL] [Abstract][Full Text] [Related]
8. OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
Ye GD; Sun GB; Jiao P; Chen C; Liu QF; Huang XL; Zhang R; Cai WY; Li SN; Wu JF; Liu YJ; Wu RS; Xie YY; Chan EC; Liou YC; Li BA
Gastroenterology; 2016 Mar; 150(3):659-671.e16. PubMed ID: 26619963
[TBL] [Abstract][Full Text] [Related]
9. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.
Sung KS; Lee YA; Kim ET; Lee SR; Ahn JH; Choi CY
Exp Cell Res; 2011 Apr; 317(7):1060-70. PubMed ID: 21192925
[TBL] [Abstract][Full Text] [Related]
10. SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies.
Liang YC; Lee CC; Yao YL; Lai CC; Schmitz ML; Yang WM
Sci Rep; 2016 May; 6():26509. PubMed ID: 27211601
[TBL] [Abstract][Full Text] [Related]
11. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
12. PML positively regulates interferon gamma signaling.
El Bougrini J; Dianoux L; Chelbi-Alix MK
Biochimie; 2011 Mar; 93(3):389-98. PubMed ID: 21115099
[TBL] [Abstract][Full Text] [Related]
13. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
14. PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53.
Wimmer P; Berscheminski J; Blanchette P; Groitl P; Branton PE; Hay RT; Dobner T; Schreiner S
Oncogene; 2016 Jan; 35(1):69-82. PubMed ID: 25772236
[TBL] [Abstract][Full Text] [Related]
15. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
16. Dual roles for lysine 490 of promyelocytic leukemia protein in the transactivation of glucocorticoid receptor-interacting protein 1.
Liu ST; Lu GY; Hsu YJ; Chang LC; Ho CL; Huang SM
Biochim Biophys Acta; 2013 Aug; 1833(8):1799-810. PubMed ID: 23542129
[TBL] [Abstract][Full Text] [Related]
17. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
18. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
[TBL] [Abstract][Full Text] [Related]
19. Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.
Xu WX; Liu SZ; Wu D; Qiao GF; Yan J
Cell Physiol Biochem; 2015; 37(4):1581-91. PubMed ID: 26517826
[TBL] [Abstract][Full Text] [Related]
20. CACUL1/CAC1 attenuates p53 activity through PML post-translational modification.
Fukuda T; Kigoshi-Tansho Y; Naganuma T; Kazaana A; Okajima T; Tsuruta F; Chiba T
Biochem Biophys Res Commun; 2017 Jan; 482(4):863-869. PubMed ID: 27889610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
